Texas

As 2018 comes to a close, analysts, journalists, investors and industry-watchers are studying their crystal balls to see what trends to watch in the upcoming year. Here are 7 trends most likely to be hitting the news cycle.

Although the size of the IPO is one aspect of determining the success of a company’s public launch, it’s not the only metric. How the stock does in the ensuing months is a very important consideration.

The Boston area, specifically Cambridge, has the highest concentration of biopharma companies in the U.S. That is followed rather closely by the San Francisco Bay Area. Many states want to encourage life science development—the return on investment can be very high, and the jobs they create are often well-paying jobs for skilled workers.

More than 200 children have died this year from influenza and 80 percent were not vaccinated, expert says.

Abeona did not specify the type of misconduct that Carsten Thiel engaged in, but it was serious enough to warrant termination.

Both the Chinese and American researchers involved in using CRISPR-Cas9 gene editing to alter the DNA of embryos for seven couples in China are under investigation. The work has also received near-universal condemnation worldwide.

Although the recent mid-term elections had a historic changeover of control in the House of Representatives from the GOP to the Democrats, at least one change in the U.S. Senate has the biopharma industry on edge. Sen. Chuck Grassley (R-Iowa) will take over as head of the Senate Finance Committee.

The Biotechnology Industry Organization (BIO) published the fifth edition of the Building the Bioeconomy report recently. The report studied 28 different indicators and provided analysis and insight into the biotech environment for 33 countries. The goal of the report is to determine how successful biotechnology sectors can be created and sustained.

Even with the Thanksgiving week, there is interesting and exciting research being conducted and published. Here’s a look.

BioSpace is proud to present its NextGen Bio “Class of 2019,” a list of 20 up-and-coming life science companies in North America that launched* no earlier than 2017.